ABEO
Price
$5.49
Change
+$0.23 (+4.37%)
Updated
May 8 closing price
Capitalization
267.91M
101 days until earnings call
RGLS
Price
$7.85
Change
-$0.00 (-0.00%)
Updated
May 8 closing price
Capitalization
543.15M
95 days until earnings call
Ad is loading...

ABEO vs RGLS

Header iconABEO vs RGLS Comparison
Open Charts ABEO vs RGLSBanner chart's image
Abeona Therapeutics
Price$5.49
Change+$0.23 (+4.37%)
Volume$1.41M
Capitalization267.91M
Regulus Therapeutics
Price$7.85
Change-$0.00 (-0.00%)
Volume$696.27K
Capitalization543.15M
ABEO vs RGLS Comparison Chart
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. RGLS commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and RGLS is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (ABEO: $5.49 vs. RGLS: $7.85)
Brand notoriety: ABEO and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 86% vs. RGLS: 30%
Market capitalization -- ABEO: $267.91M vs. RGLS: $543.15M
ABEO [@Biotechnology] is valued at $267.91M. RGLS’s [@Biotechnology] market capitalization is $543.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileRGLS’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • RGLS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABEO and RGLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 7 TA indicator(s) are bullish while RGLS’s TA Score has 4 bullish TA indicator(s).

  • ABEO’s TA Score: 7 bullish, 3 bearish.
  • RGLS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than RGLS.

Price Growth

ABEO (@Biotechnology) experienced а -20.09% price change this week, while RGLS (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

RGLS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGLS($543M) has a higher market cap than ABEO($268M). RGLS YTD gains are higher at: 396.835 vs. ABEO (-1.436). RGLS has higher annual earnings (EBITDA): -45.85M vs. ABEO (-64.95M). ABEO has more cash in the bank: 110M vs. RGLS (75.8M). RGLS has less debt than ABEO: RGLS (274K) vs ABEO (23.1M). ABEO (0) and RGLS (0) have equivalent revenues.
ABEORGLSABEO / RGLS
Capitalization268M543M49%
EBITDA-64.95M-45.85M142%
Gain YTD-1.436396.835-0%
P/E RatioN/AN/A-
Revenue00-
Total Cash110M75.8M145%
Total Debt23.1M274K8,431%
FUNDAMENTALS RATINGS
ABEO vs RGLS: Fundamental Ratings
ABEO
RGLS
OUTLOOK RATING
1..100
6931
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
5034
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
21n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (62) in the Pharmaceuticals Generic industry is in the same range as RGLS (62) in the Pharmaceuticals Other industry. This means that ABEO’s stock grew similarly to RGLS’s over the last 12 months.

RGLS's Profit vs Risk Rating (81) in the Pharmaceuticals Other industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that RGLS’s stock grew similarly to ABEO’s over the last 12 months.

RGLS's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as ABEO (97) in the Pharmaceuticals Generic industry. This means that RGLS’s stock grew similarly to ABEO’s over the last 12 months.

RGLS's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as ABEO (50) in the Pharmaceuticals Generic industry. This means that RGLS’s stock grew similarly to ABEO’s over the last 12 months.

RGLS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that RGLS’s stock grew similarly to ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEORGLS
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIPTX16.34N/A
N/A
Virtus KAR Global Quality Dividend I
STSAX6.48N/A
N/A
Allspring Common Stock C
SOPYX30.93N/A
N/A
ClearBridge Dividend Strategy I
PRASX17.26N/A
N/A
T. Rowe Price New Asia
FAEVX23.63N/A
N/A
Fidelity Advisor Equity Value Z

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ELVN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+4.27%
ELVN - ABEO
47%
Loosely correlated
+1.97%
ERAS - ABEO
43%
Loosely correlated
+13.47%
APGE - ABEO
43%
Loosely correlated
+7.29%
RGLS - ABEO
42%
Loosely correlated
N/A
RCKT - ABEO
42%
Loosely correlated
+11.57%
More

RGLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGLS has been loosely correlated with ABEO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RGLS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
N/A
ABEO - RGLS
42%
Loosely correlated
+4.27%
NKTX - RGLS
37%
Loosely correlated
+4.28%
KYMR - RGLS
36%
Loosely correlated
+5.70%
CRNX - RGLS
32%
Poorly correlated
+4.17%
INZY - RGLS
31%
Poorly correlated
-6.77%
More